Association of Prior PARP Inhibitor Exposure with Clinical Outcomes After ¹⁷⁷Lu-PSMA-617 in Men with Castration-resistant Prostate Cancer and Mutations in DNA Homologous Recombination Repair Genes.

IF 8.3 1区医学 Q1 ONCOLOGY

European urology oncology Pub Date : 2025-05-06 DOI:10.1016/j.euo.2025.02.017

Mona Kafka, Giulia Giannini, Isabel Heidegger

引用次数: 0

查看原文本刊更多论文

PARP抑制剂暴露与去势抵抗前列腺癌患者177Lu-PSMA-617术后临床结果的关系及DNA同源重组修复基因突变

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European urology oncology Multiple-

CiteScore

15.50

自引率

2.40%

发文量

128

审稿时长

20 days

期刊介绍： Journal Name: European Urology Oncology Affiliation: Official Journal of the European Association of Urology Focus: First official publication of the EAU fully devoted to the study of genitourinary malignancies Aims to deliver high-quality research Content: Includes original articles, opinion piece editorials, and invited reviews Covers clinical, basic, and translational research Publication Frequency: Six times a year in electronic format

Association of Prior PARP Inhibitor Exposure with Clinical Outcomes After 177Lu-PSMA-617 in Men with Castration-resistant Prostate Cancer and Mutations in DNA Homologous Recombination Repair Genes.

Association of Prior PARP Inhibitor Exposure with Clinical Outcomes After ¹⁷⁷Lu-PSMA-617 in Men with Castration-resistant Prostate Cancer and Mutations in DNA Homologous Recombination Repair Genes.